Published in Cancer Epidemiol Biomarkers Prev on October 01, 2005
Human flavin-containing monooxygenase 2.1 catalyzes oxygenation of the antitubercular drugs thiacetazone and ethionamide. Drug Metab Dispos (2008) 0.90
Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives. Pharmacogenomics (2007) 0.90
Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention. Cancer Prev Res (Phila) (2011) 0.89
Relationships between flavin-containing mono-oxygenase 3 (FMO3) genotype and trimethylaminuria phenotype in a Japanese population. Br J Clin Pharmacol (2014) 0.83
Risk modification of colorectal adenoma by CYP7A1 polymorphisms and the role of bile acid metabolism in carcinogenesis. Cancer Prev Res (Phila) (2011) 0.82
Pharmacogenetics and diseases of the colon. Curr Opin Gastroenterol (2007) 0.81
Effects of FMO3 Polymorphisms on Pharmacokinetics of Sulindac in Chinese Healthy Male Volunteers. Biomed Res Int (2017) 0.75
A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med (2003) 9.18
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med (2000) 7.54
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med (2003) 6.99
Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med (1993) 6.13
Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med (2002) 3.16
Chemoprevention of colorectal cancer. N Engl J Med (2000) 1.98
COX-2 inhibition and colorectal cancer. Semin Oncol (2004) 1.53
Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology (2002) 1.45
Familial adenomatous polyposis. Gastrointest Endosc (2003) 1.22
Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma. J Natl Cancer Inst (2005) 1.20
Trimethylaminuria and a human FMO3 mutation database. Hum Mutat (2003) 1.20
Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig Dis Sci (1998) 1.15
Identification of the biologically active form of sulindac. J Pharmacol Exp Ther (1977) 1.14
Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation. Drug Metab Dispos (2002) 1.12
Recent studies on the structure and function of multisubstrate flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol (1993) 1.08
Tissue prostanoids as biomarkers for chemoprevention of colorectal neoplasia: correlation between prostanoid synthesis and clinical response in familial adenomatous polyposis. Prostaglandins Other Lipid Mediat (2000) 1.08
Reduction of Sulindac to its active metabolite, sulindac sulfide: assay and role of the methionine sulfoxide reductase system. Biochem Biophys Res Commun (2003) 1.08
Differential developmental and tissue-specific regulation of expression of the genes encoding three members of the flavin-containing monooxygenase family of man, FMO1, FMO3 and FM04. Eur J Biochem (1996) 1.02
Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis. Gastroenterology (2004) 1.01
Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Gut (1996) 1.01
The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development. Drug Discov Today (2004) 0.98
Colorectal cancer chemoprevention--an overview of the science. Gastroenterology (2004) 0.97
Genetic polymorphisms in carcinogen metabolism and their association to hereditary nonpolyposis colon cancer. Gastroenterology (1998) 0.95
Nonsteroidal anti-inflammatory drugs and prevention of colorectal cancer. Curr Gastroenterol Rep (1999) 0.93
Cyclooxygenase-2 and colorectal cancer. Prog Exp Tumor Res (2003) 0.91
Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism. Clin Pharmacol Ther (1999) 0.90
Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes. Biochem Pharmacol (2000) 0.90
Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis. Clin Cancer Res (2004) 0.85
Glutathione S-transferase Mu phenotype in patients with familial adenomatous polyposis and in unaffected controls. Cancer Detect Prev (1994) 0.79
Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention. Cancer Chemother Biol Response Modif (2003) 0.78
Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology (2008) 15.86
Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin (2008) 12.90
Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology (2012) 8.51
Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science (2003) 6.85
The zinc-finger transcription factor Klf4 is required for terminal differentiation of goblet cells in the colon. Development (2002) 5.09
Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA (2006) 4.34
Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol (2006) 4.22
Mammalian Krüppel-like factors in health and diseases. Physiol Rev (2010) 4.09
Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res (2006) 3.81
Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum (2006) 3.64
A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum (2002) 3.55
Small changes in expression affect predisposition to tumorigenesis. Nat Genet (2001) 3.37
Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med (2002) 3.16
Fluid overload before continuous hemofiltration and survival in critically ill children: a retrospective analysis. Crit Care Med (2004) 3.15
Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol (2004) 3.10
Identification of Krüppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer. Oncogene (2004) 2.96
Krüppel-like factors 4 and 5: the yin and yang regulators of cellular proliferation. Cell Res (2005) 2.73
Vertebral osteomyelitis: long-term outcome for 253 patients from 7 Cleveland-area hospitals. Clin Infect Dis (2002) 2.59
Ultrasound-guided central venous catheter placement decreases complications and decreases placement attempts compared with the landmark technique in patients in a pediatric intensive care unit. Crit Care Med (2009) 2.47
Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila) (2008) 2.47
The diverse functions of Krüppel-like factors 4 and 5 in epithelial biology and pathobiology. Bioessays (2007) 2.40
Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab (2004) 2.39
Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology (2008) 2.31
Kruppel-like factor 4 mediates p53-dependent G1/S cell cycle arrest in response to DNA damage. J Biol Chem (2002) 2.19
NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw (2010) 2.13
Transcriptional profiling of Krüppel-like factor 4 reveals a function in cell cycle regulation and epithelial differentiation. J Mol Biol (2003) 2.11
Overexpression of Krüppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenecity. Oncogene (2003) 2.11
Loss of imprinting of insulin growth factor II gene: a potential heritable biomarker for colon neoplasia predisposition. Gastroenterology (2004) 2.06
Novel cross talk of Kruppel-like factor 4 and beta-catenin regulates normal intestinal homeostasis and tumor repression. Mol Cell Biol (2006) 1.96
Cardiovascular status of infants and children of women infected with HIV-1 (P(2)C(2) HIV): a cohort study. Lancet (2002) 1.83
The incidence and prevalence of systemic lupus erythematosus, 2002-2004: The Georgia Lupus Registry. Arthritis Rheumatol (2014) 1.83
Impact of genetic counseling and testing on colorectal cancer screening behavior. Genet Test (2002) 1.81
Incidence of cardiac abnormalities in children with human immunodeficiency virus infection: The prospective P2C2 HIV study. J Pediatr (2002) 1.80
Requirement of Krüppel-like factor 4 in preventing entry into mitosis following DNA damage. J Biol Chem (2003) 1.76
Krüppel-like factor 6 regulates mitochondrial function in the kidney. J Clin Invest (2015) 1.72
Haploinsufficiency of Krüppel-like factor 4 promotes adenomatous polyposis coli dependent intestinal tumorigenesis. Cancer Res (2007) 1.71
Krüppel-like factor 5 mediates the transforming activity of oncogenic H-Ras. Oncogene (2004) 1.70
High incidence of microsatellite instability in colorectal cancer from African Americans. Clin Cancer Res (2003) 1.68
Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst (2007) 1.65
Opposing effects of Krüppel-like factor 4 (gut-enriched Krüppel-like factor) and Krüppel-like factor 5 (intestinal-enriched Krüppel-like factor) on the promoter of the Krüppel-like factor 4 gene. Nucleic Acids Res (2002) 1.64
Risk of colorectal cancer in juvenile polyposis. Gut (2007) 1.64
Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol. Hepatology (2012) 1.64
Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology (2004) 1.62
Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med (2003) 1.60
Krüppel-like factor 5 mediates cellular transformation during oncogenic KRAS-induced intestinal tumorigenesis. Gastroenterology (2007) 1.58
Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol (2006) 1.57
The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer. Gastroenterology (2009) 1.56
Human cancer cells commonly acquire DNA damage during mitotic arrest. Cancer Res (2007) 1.47
Notch inhibits expression of the Krüppel-like factor 4 tumor suppressor in the intestinal epithelium. Mol Cancer Res (2008) 1.46
Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology (2002) 1.45
Neuroendocrine dysfunction in pediatric critical illness. Pediatr Crit Care Med (2009) 1.45
Near IR heptamethine cyanine dye-mediated cancer imaging. Clin Cancer Res (2010) 1.44
Krüppel-like factor 4 prevents centrosome amplification following gamma-irradiation-induced DNA damage. Oncogene (2005) 1.40
Relationships between beliefs about medications and adherence. Am J Health Syst Pharm (2009) 1.39
Perceptions of genetic discrimination among at-risk relatives of colorectal cancer patients. Genet Med (2004) 1.39
Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting. Genet Med (2011) 1.37
The rate of bloodstream infection is high in infants with short bowel syndrome: relationship with small bowel bacterial overgrowth, enteral feeding, and inflammatory and immune responses. J Pediatr (2010) 1.36
All-trans retinoic acid inhibits proliferation of intestinal epithelial cells by inhibiting expression of the gene encoding Kruppel-like factor 5. FEBS Lett (2004) 1.35
KLF4 suppresses transformation of pre-B cells by ABL oncogenes. Blood (2006) 1.33
Usefulness of the peak velocity difference by tissue Doppler imaging technique as an effective predictor of response to cardiac resynchronization therapy. Am J Cardiol (2004) 1.33
Occurrence of colorectal adenomas in younger adults: an epidemiologic necropsy study. Clin Gastroenterol Hepatol (2008) 1.32
Krüppel-like factor 5 promotes mitosis by activating the cyclin B1/Cdc2 complex during oncogenic Ras-mediated transformation. FEBS Lett (2005) 1.31
Sox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells. Mol Cancer Res (2008) 1.30
Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: the prospective P2C2 HIV Multicenter Study. Am Heart J (2005) 1.30
Haploinsufficiency of Krüppel-like factor 5 rescues the tumor-initiating effect of the Apc(Min) mutation in the intestine. Cancer Res (2009) 1.29
Enterocyte differentiation marker intestinal alkaline phosphatase is a target gene of the gut-enriched Kruppel-like factor. Am J Physiol Gastrointest Liver Physiol (2003) 1.29
Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Krüppel-like factor 5. J Biol Chem (2007) 1.29
Kruppel-like factor 5 is an important mediator for lipopolysaccharide-induced proinflammatory response in intestinal epithelial cells. Nucleic Acids Res (2006) 1.28
Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans. Int J Cancer (2005) 1.26
Juvenile polyposis syndrome. World J Gastroenterol (2011) 1.26
Conditioning protects C. elegans from lethal effects of enteropathogenic E. coli by activating genes that regulate lifespan and innate immunity. Cell Host Microbe (2009) 1.25
Coagulopathy is prevalent and associated with adverse outcomes in transfused pediatric trauma patients. J Pediatr (2011) 1.23
Familial adenomatous polyposis. Gastrointest Endosc (2003) 1.22
Wnt11 signaling promotes proliferation, transformation, and migration of IEC6 intestinal epithelial cells. J Biol Chem (2004) 1.22
Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism. Clin Cancer Res (2005) 1.21
Reduction in fear of falling through intense tai chi exercise training in older, transitionally frail adults. J Am Geriatr Soc (2005) 1.20
p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res (2007) 1.20
Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine (2007) 1.19
Gastrointestinal polyposis syndromes. Curr Mol Med (2007) 1.18
SUMOylation regulates nuclear localization of Krüppel-like factor 5. J Biol Chem (2008) 1.18
Chemoprevention in familial adenomatous polyposis. Best Pract Res Clin Gastroenterol (2011) 1.17
Selective retention of bone marrow-derived cells to enhance spinal fusion. Clin Orthop Relat Res (2005) 1.17
Genetic testing for hereditary colorectal cancer in children: long-term psychological effects. Am J Med Genet A (2003) 1.15
The role of Krüppel-like factors in the reprogramming of somatic cells to induced pluripotent stem cells. Histol Histopathol (2009) 1.15
Appearance of dextranomer/hyaluronic Acid copolymer implants on computerized tomography after endoscopic treatment of vesicoureteral reflux in children. J Urol (2009) 1.15
The influence of intense Tai Chi training on physical performance and hemodynamic outcomes in transitionally frail, older adults. J Gerontol A Biol Sci Med Sci (2006) 1.15
Altered intestinal epithelial homeostasis in mice with intestine-specific deletion of the Krüppel-like factor 4 gene. Dev Biol (2010) 1.14
Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 1.12
Chemoprevention strategies using NSAIDs and COX-2 inhibitors. Cancer Biol Ther (2003) 1.11
Krüppel-like factor 5 mediates transmissible murine colonic hyperplasia caused by Citrobacter rodentium infection. Gastroenterology (2008) 1.11
Rapid development of colorectal neoplasia in patients with Lynch syndrome. Clin Gastroenterol Hepatol (2010) 1.11
Krüppel-like factor 5 is important for maintenance of crypt architecture and barrier function in mouse intestine. Gastroenterology (2011) 1.10
Do red cell transfusions increase the risk of necrotizing enterocolitis in premature infants? J Pediatr (2010) 1.10